HC Wainwright Cuts Aptose Biosciences (NASDAQ:APTO) Price Target to $2.00

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its target price lowered by HC Wainwright from $7.00 to $2.00 in a research report released on Wednesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on Aptose Biosciences in a research report on Wednesday, November 13th. They issued a “hold” rating for the company.

Aptose Biosciences Price Performance

APTO opened at $0.27 on Wednesday. The company has a 50-day moving average of $0.38 and a 200-day moving average of $0.62. Aptose Biosciences has a 1-year low of $0.27 and a 1-year high of $2.91.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp boosted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.